Introduction
Retatrutide is a synthetic triagonist peptide that simultaneously activates three receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). As the first triple incretin receptor agonist to enter advanced research, Retatrutide represents a significant evolution beyond dual agonists such as Tirzepatide, offering a unique pharmacological profile with potential applications across metabolic, hepatic, and cardiovascular research.
For research and laboratory use only. Not intended for human or veterinary administration.
Molecular Structure
Retatrutide is a 36-amino acid acylated peptide engineered for balanced triagonist activity:
- Triagonist design: Amino acid sequence and substitutions are optimised to provide meaningful agonist activity at all three target receptors — GLP-1R, GIPR, and GCGR — rather than full agonism at one with partial activity at others.
- Fatty acid acylation: A C20 fatty acid chain enables albumin binding, extending the half-life to approximately 6 days.
- DPP-4 resistance: Structural modifications confer resistance to enzymatic degradation.
Triple Receptor Pharmacology
GLP-1 Receptor (GLP-1R)
GLP-1R activation contributes appetite suppression, glucose-dependent insulin secretion, glucagon inhibition, and delayed gastric emptying — the established mechanisms of the GLP-1 agonist class.
GIP Receptor (GIPR)
GIPR activation provides synergistic insulin secretion, adipose tissue modulation, and potential central nervous system effects on appetite and energy homeostasis, as characterised in Tirzepatide research.
Glucagon Receptor (GCGR)
The addition of glucagon receptor agonism is the key differentiator of Retatrutide from dual agonists. Glucagon receptor activation contributes:
- Increased energy expenditure: Glucagon stimulates thermogenesis in brown adipose tissue and increases basal metabolic rate.
- Hepatic fat reduction: Glucagon promotes hepatic fatty acid oxidation and reduces hepatic lipid accumulation — of particular interest in NASH/NAFLD research models.
- Lipolysis: Glucagon stimulates lipolysis in white adipose tissue, contributing to fat mass reduction.
- Appetite modulation: Central glucagon receptor signalling contributes additional appetite-suppressing effects.
Research Applications
Metabolic Research
- Obesity models — preclinical data suggests superior body weight reduction compared to dual agonists, attributed to the additional energy expenditure from glucagon receptor activation.
- Type 2 diabetes models — improved glycaemic control through complementary insulin secretion mechanisms.
- Adipose tissue biology — differential effects on white and brown adipose tissue through combined GIPR and GCGR activation.
Hepatic Research
- NASH and NAFLD models — the combination of GLP-1R-mediated insulin sensitisation and GCGR-mediated hepatic fat oxidation makes Retatrutide of particular interest in liver disease research.
- Hepatic steatosis — dose-dependent reductions in liver fat content in diet-induced models.
- Hepatic inflammation and fibrosis markers in NASH progression models.
Cardiovascular Research
- Atherosclerosis models — combined lipid-lowering and anti-inflammatory effects.
- Cardiac energy metabolism — glucagon receptor expression in cardiac tissue makes Retatrutide of interest in heart failure and ischaemia models.
- Blood pressure and vascular function research.
Available Concentrations for Research
Vanta Labs supplies Retatrutide across an extensive concentration range to support dose-response, chronic dosing, and comparative research designs: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg.
Storage and Handling
Store lyophilised Retatrutide at −20°C, protected from light and moisture. Reconstitute with bacteriostatic water. Once reconstituted, store at 2–8°C and use within 28 days. Avoid repeated freeze-thaw cycles and agitation.
All products supplied by Vanta Labs are intended strictly for laboratory and research purposes.